Investing.com - HTG Molecular Diagnostics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
HTG Molecular Diagnostics announced earnings per share of $-0.410 on revenue of $1.25M. Analysts polled by Investing.com anticipated EPS of $-0.585 on revenue of $2.83M.
HTG Molecular Diagnostics shares are down 53.92% from the beginning of the year , still down 91.20% from its 52 week high of $5.68 set on Monday, January 3, 2022.
HTG Molecular Diagnostics follows other major Healthcare sector earnings this month
HTG Molecular Diagnostics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar